Tumgik
#biogen
don-lichterman · 2 years
Text
Biogen Explores Music Therapy To Improve Walking In MS Through Partnership With MedRythms
Biogen Explores Music Therapy To Improve Walking In MS Through Partnership With MedRythms
Young caucasian woman listening music at home. getty Today marks the fourteenth annual World MS Day – a day to reflect on the experiences, challenges and aspirations of the 2.5 million people around the world living with multiple sclerosis. A neurological condition principally diagnosed in adults between the ages of 20 and 40 – some of the disease’s defining features and hardest to treat…
View On WordPress
2 notes · View notes
caregivervent · 2 months
Text
Controversial Alzheimer's drug Aduhelm to be discontinued by Biogen
The rocky road that the Alzheimer’s drug Aduhelm experienced on its way to FDA approval was considered a hard-fought victory by proponents, but skeptics and critics may feel redeemed as Biogen announced Jan. 31 that it will discontinue production and research of the controversial drug. Biogen’s announcement to abandon Aduhelm comes just two and a half years after the drug received accelerated…
Tumblr media
View On WordPress
0 notes
usnewsper-health · 2 months
Text
Controversial Alzheimer's Drug Fails Trial: Challenges in Finding Effective Treatment #aducanumab #Aduhelm #Alzheimersdrug #betaamyloidplaques #Biogen #challenges #clinicaltrial #cognitivedecline #effectiveness #fasttrackstatus #FDA #Innovation #Research #sideeffects #Treatment
0 notes
Text
蘋果可能運用Vision Pro和Apple Watch結合,於心理健康診斷與療程的創新應用
蘋果可能運用Vision Pro和Apple Watch結合,於心理健康診斷與療程的創新應用 Apple may use Vision Pro and Apple Watch to create innovative applications for mental health diagnosis and treatment
蘋果正積極探索將其Vision Pro技術應用於心理健康管理領域,期望借此打造前所未有的創新健康照護體驗。有內部消息人士透露,蘋果計劃利用Vision Pro的攝像頭和感測器,來捕捉使用者的情緒變化,並透過分析心率變異性(HRV),以偵測出憂鬱、焦慮、壓力以及創傷後壓力症候群等心理健康問題的徵兆。 為了更全面地支援使用者的心理健康,蘋果正在研究將Vision Pro與Apple Watch結合使用。這種結合不僅能夠提供嶄新的治療方法,還能在檢測到心理健康問題時,立即展示圖像和聲音,以改善使用者的情緒。 在 iPhone 上的「健康」中追蹤你的心理安康情況 你可以使用「健康」App 來反思自己的感受,並記錄你的瞬間情緒和每日心情。你也可以瞭解自己的心理狀態與生活方式因素的可能關聯性,例如運動、睡眠、日光照射時間和正念分鐘數。…
Tumblr media
View On WordPress
0 notes
deinheilpraktiker · 6 months
Text
Eine neue genetisch zielgerichtete MND-Therapie könnte einen Wendepunkt für die Patientenversorgung bedeuten
Wissenschaftler glauben, dass eine neue genetisch zielgerichtete Therapie zur Behandlung von Motoneuronerkrankungen (MND) einen Wendepunkt für die Patientenversorgung darstellen könnte, nachdem die Ergebnisse einer klinischen Phase-3-Studie nach 12 Monaten erhebliche körperliche Vorteile für Patienten gezeigt haben. Forscher des Sheffield Institute for Translational Neuroscience (SITraN) fanden…
Tumblr media
View On WordPress
0 notes
opennewspaper · 9 months
Text
Rivian, Levi Strauss, Biogen, First Solar and more
A Rivian logo on an Amazon.com delivery electric van photographed in Chicago, Illinois, on July 21, 2022. Jamie Kelter Davis | Bloomberg | Getty Images Check out the companies making headlines in midday trading. Alibaba — U.S. shares of the Chinese company added 8.8% in afternoon trading. Earlier on Friday, Reuters first reported that Alibaba’s affiliate company, Ant Group, would pay a $984…
View On WordPress
0 notes
biglisbonnews · 1 year
Photo
Tumblr media
FDA’s approval of Friedreich’s ataxia drug is a game changer for treatment of rare diseases A drug to treat a rare neurological disorder has only had to jump through one hoop—read: clinical trial—instead of the recommended two to win regulatory approval.Read more... https://qz.com/fda-approval-friedreich-s-ataxia-drug-reata-skyclarys-1850171937
0 notes
invertiryespecular · 1 year
Text
Biogen a las puertas de aprobar un medicamento contra el Alzheimer
Biogen a las puertas de aprobar un medicamento contra el Alzheimer
INVESTING.- Los fabricantes de medicamentos Eisai Co Ltd y Biogen (NASDAQ:BIIB) informaron en septiembre de que su terapia lecanemab podía ralentizar el avance de la enfermedad en un 27% en 18 meses en comparación con un placebo. El hallazgo valida la teoría de que la eliminación de la proteína amiloide que forma cúmulos en el cerebro de los pacientes de alzhéimer podría ralentizar o detener la…
Tumblr media
View On WordPress
0 notes
sciencefor2 · 1 year
Text
Is the drug ADUHELM a definitive cure for Alzheimer's?
This is a topic that has made me very curious. As a family member who has seen Alzheimer's disease up close in a loved one, it seems like good news, but as a scientist interested in the #neuro world, I can't disagree more with everything related to this "new treatment."
🌐Alzheimer's disease is the most prevalent form of dementia, with 50 million people affected worldwide. This means that there is a new case of Alzheimer's every 3 seconds and scientists estimate that by 2050 this community will increase to 152 million.
🗯️Although several approaches have been developed to combat Alzheimer's, no successful drug treatment has yet been found to slow or stop the damage and destruction of neurons, and only palliative therapies are used. Therefore, until June 2021, the FDA approves Aduhelm (human monoclonal antibody) from Biogen Pharmaceuticals.
🤔Its approval has generated much controversy, as there is a lack of positive data favoring the disappearance of beta-amyloid protein accumulation. Moreover, in some cases, side effects can lead to severe neurological damage. Studies contradict each other, and this alone leads me as a scientist passionate about seeking and contrasting information to #doubt everything I see and read.
🟥In the last move, the EMA, on December 16, 2021, published an article rejecting #Aduhelm as a treatment for Alzheimer's since, in the words of the agency, "the benefits of Aduhelm do not outweigh its risks and it is recommended to deny marketing authorization." You can read it here: https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/aduhelm
And the company withdrew the marketing authorization application on April 20, 2022.
✅In my opinion, the EMA has been rigorous, scientifically speaking. You cannot approve a treatment simply because there is a lack of one for that disease. However, if you have seen a decrease in "symptoms," you should refine the molecule so that the effects are more evident.
What would you guys do in a situation like this? What do you think about the FDA approving a treatment for which we have insufficient evidence that it works? I'll read you in the comments 👇
Tumblr media
¿Es el fármaco ADUHELM una cura definitiva para el Alzheimer?
Esto es un tema que me ha suscitado mucha curiosidad y como familiar que ha visto de cerca la enfermedad de Alzheimer en un ser querido, parece una buena noticia, pero como científica interesada en el mundo #neuro no puedo estar en más desacuerdo con todo lo relacionado a este “nuevo tratamiento”.
🌐La enfermedad de Alzheimer es la forma más prevalente de demencia, con 50 millones de personas afectadas en todo el mundo. Esto significa que hay un caso reciente de Alzheimer cada 3 segundos y los científicos estiman que en 2050 esta comunidad aumentará a 152 millones.
🗯️Aunque se han desarrollado varios enfoques para combatir el Alzheimer, aún no se ha encontrado un tratamiento farmacológico exitoso que frene o detenga el daño y la destrucción de las neuronas, y sólo se utilizan terapias paliativas. Hasta que, en junio de 2021, la FDA aprueba Aduhelm (anticuerpo monoclonal humano) de la farmacéutica Biogen.
🤔Su aprobación ha generado mucha controversia, ya que hay escasez de datos #positivos que favorezcan la desaparición de la acumulación de proteínas beta-amiloide. Además, en algunos casos, los efectos secundarios pueden provocar graves lesiones neurológicas. Los estudios se contradicen unos y otros y esto solo me lleva a mí como científica y apasionada de buscar y contrastar información a #dudar de todo lo que veo y leo.
🟥En un último movimiento la #EMA, a 16 de diciembre de 2021, publica un artículo rechazando #Aduhelm como tratamiento para el Alzheimer ya que, en palabras de la agencia, “los beneficios de Aduhelm no superan sus riesgos y se recomienda denegar la autorización de comercialización”. Podéis leerlo aquí: https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/aduhelm
Y la empresa retiró la solicitud de autorización de comercialización finalmente el 20 de abril de 2022.
✅En mi opinión, la EMA ha sido rigurosa, científicamente hablando. No se puede aprobar un tratamiento sencillamente porque haya una falta de uno para esa enfermedad en concreto. Sin embargo, si de verdad se ha visto una disminución de los “síntomas” se debería refinar la molécula para que los efectos sean más claros.
¿Vosotros qué haríais en una situación así? ¿Qué opináis sobre la FDA aprobando un tratamiento del cual no tenemos pruebas suficientes de que funcione? Os leo en comentarios 👇
1 note · View note
hrishikeshqmi · 1 year
Text
https://newsmantraa.us/auto-injectors-market-share-size-recent-trends-financial-summaries-analysis-global-players-are-amgen-teva-biogen-eli-lilly-mylan-merck-shl-group-ypsomed-astrazeneca-becton-dickinson-and/
Auto injectors Market Share, Size, Recent Trends, Financial Summaries Analysis , Global Players are Amgen, Teva, Biogen, Eli Lilly, Mylan, Merck, SHL Group, Ypsomed, AstraZeneca, Becton Dickinson and Company.
0 notes
biogen1 · 1 year
Text
Black Seed Extract
1. Biogen products are some of the most popular and well-known supplements on the market. This is likely because they offer a variety of benefits that can be beneficial to both your body and mind.
2. One biogen product that offers many benefits is black seed extract. This extract has been shown to improve overall health and wellbeing, including reducing inflammation and supporting cognitive function.
What is black seed extract and what are its benefits?
Black seed extract (BSE) is a plant-based compound with anti-inflammatory and anti-cancer properties. It has been used in traditional medicine for centuries, and recent studies suggest that it may also have anti-aging properties. BSE is available as a dietary supplement, and research suggests that it may be beneficial for reducing inflammation, promoting healthy skin, preventing chronic diseases, and improving cognitive function.
What are the key components of black seed extract?
Black seed oil is becoming increasingly popular as a natural remedy for a variety of ailments. This oil is derived from the seeds of the black needlerush plant. The constituents of black seed oil that have attracted most attention are its cannabinoids, which are believed to have therapeutic effects on a variety of conditions. These include reducing inflammation, treating anxiety and depression, and helping to improve skin health. There are also reports that it can help to protect against cancer and improve heart health. The key components of black seed oil that contribute to its various benefits are the cannabinoids, fatty acids, and minerals.
Nigella Sativa Extract is an ancient Indian spice that benefits the digestive system and relieves you from indigestion. The seeds help in lowering cholesterol levels, curbing appetite and boosting metabolism. It helps in treating stomach ulcers and other health problems related to digestion.
How can black seed extract help improve health?
Black seed oil is derived from the seeds of Nigella Sativa, a flowering plant in the Ranunculaceae family. The plant is native to the Mediterranean region and parts of Asia. The oil has been used for centuries as a culinary and medicinal herb. Recent studies have shown that black seed oil can help improve health.
One study found that black seed oil can help improve heart health by reducing bad cholesterol levels and increasing good cholesterol levels. Black seed oil also helps reduce inflammation, which can lead to heart disease, stroke, and other diseases.
Another study found that black seed oil can help improve joint health by reducing inflammation and improving joint function. Black seed oil also has anti-inflammatory properties, which can help reduce pain in joints.
Are there any side effects to taking black seed extract?
There are many purported benefits to black seed oil, including acting as an anti-inflammatory, reducing anxiety and improving blood circulation. However, as with most supplements, there are potential side effects that should be considered before taking black seed extract. While not all of the side effects listed below have been observed in all individuals, they should be taken into account when considering whether or not to take black seed extract. Side effects that have been reported include stomach upset, changes in heart rate and blood pressure, and a decrease in testosterone levels in men. It is also important to note that some people may experience more than one side effect from black seed oil supplementation. Therefore, it is always recommended that you speak with your doctor before beginning any supplement regimen.
Conclusion
Black seed extract has a variety of benefits for both the body and mind. These include improved heart health, better cognitive function, and relief from anxiety and depression. These benefits make black seed extract a valuable addition to any healthy diet or routine. If you're looking for ways to improve your health, give black seed extract a try!
0 notes
thejewishlink · 1 year
Text
Alzheimer’s Drug Shows Promise in Early Results of Study
Alzheimer’s Drug Shows Promise in Early Results of Study
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study. Eisai announced results late Tuesday from a global study of nearly 1,800 people with early-stage Alzheimer’s. The drugmaker said early results showed that its treatment, lecanemab,…
Tumblr media
View On WordPress
0 notes
mariebenz · 2 years
Text
BIOGEN: Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
Tumblr media
MedicalResearch.com Interview with:
Tumblr media
Dr. Franchimont Nathalie Franchimont, M.D., Ph.D. Senior Vice President, Head of Multiple Sclerosis and Immunology Head of the Multiple Sclerosis and Immunology Development Unit Biogen MedicalResearch.com: What is the background for this study? What are the main findings? Response: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organ systems. Rash and arthritis are among the most frequent manifestations of the disease and severe organ damage can also occur especially when organs like the kidney are affected. Litifilimab (known as BIIB059) is a monoclonal antibody being studied for the potential treatment of SLE and cutaneous lupus erythematosus (CLE). The Phase 2 LILAC study evaluated litifilimab versus placebo in two parts: Part A in participants who have SLE with active joint and skin manifestations; and Part B in participants with active CLE, including chronic and subacute subtypes, with or without other organ involvement. Results from the SLE portion of the study (Part A) show litifilimab met the study’s primary endpoint by significantly reducing total active joint count compared to placebo. Total active joint count was defined as the total number of tender or swollen joints. Litifilimab was generally well tolerated, with most reported adverse events (AEs) rated as mild or moderate. Note, this Phase 2 trial was not powered to assess secondary endpoints. Based on these positive Phase 2 results, Biogen is currently enrolling participants into the Phase 3 TOPAZ-1 and TOPAZ-2 studies, which will evaluate the efficacy and safety of litifilimab in participants with active SLE worldwide. Part B results from LILAC were published separately in NEJM on July 28, 2022 and expand the body of evidence supporting litifilimab as a potential first-in-class therapy for cutaneous lupus erythematosus in addition to SLE. MedicalResearch.com: What should readers take away from your report? Response: Litifilimab, discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and is being investigated for the potential treatment of SLE and CLE. Litifilimab targets a receptor that is predominately expressed on a subset of immune cells, called plasmacytoid dendritic cells (pDCs), that are found at the site of inflammation in key organs affected by lupus including the joints and skin. In SLE, results from LILAC showed via an organ specific approach that litifilimab administration was associated with a decrease in total active joint counts. We are pleased that the NEJM has published the totality of data from the LILAC program which reinforces our belief in the potential of litifilimab as a first-in-class therapy for both systemic and cutaneous lupus. The encouraging results from the Phase 2 LILAC study provide support for us to further characterize the safety and efficacy of litifilimab in longer and larger studies in both SLE and CLE. To. Biogen is currently enrolling participants into the Phase 3 TOPAZ-1 (NCT04895241) and TOPAZ-2 (NCT04961567) studies, which will evaluate the efficacy and safety of litifilimab in participants with active SLE at 269 clinical trial sites worldwide. We are initiating a pivotal study of litifilimab in CLE in 2022 (NCT05531565). Lupus is a chronic autoimmune disease that disproportionately affects women and people of color who have historically been underserved in medicine and face greater challenges accessing care. There is currently no cure. Lupus can cause debilitating symptoms and irreversible skin and organ damage which, if left untreated, can have a lasting negative impact on functional and psychological aspects of people’s lives. Despite advancements over the past two decades in treating autoimmune indications, both SLE and CLE represent a high unmet medical need. MedicalResearch.com: What recommendations do you have for future research as a results of this study? Response: Lupus is a complex disease affecting multiple system/organs. In recent years, a growing body of evidence from lupus clinical research has shown that there are multiple clinical phenotypes /endotypes, for whom symptoms development may involve different cellular pathways in the innate and/or adaptive immune system. As a consequence, not all patients may respond to one specific drug. To help people living with lupus and treating physicians get the appropriate treatment to rapidly control the disease activity and avoid damage, it is important to further understand what parameters (clinical, genetic biomarkers, etc.) are associated with a response to treatment. In addition, further mechanistic investigation is needed to better understand the role of pDCs in lupus. MedicalResearch.com: Is there anything else you would like to add? Any disclosures? Response: At Biogen, our goal is to discover and develop new treatment options that not only reduce lupus disease activity but also decrease clinical manifestations that impact patients the most. Decades of study on pathways at the intersection of neurology and immunology have provided Biogen with expertise in specialized immunology. We are currently advancing two lupus therapies – litifilimab and dapirolizumab pegol (being developed in collaboration with UCB) – in Phase 3 trials. We look forward to continuing our evaluation of litifilimab in Phase 3 studies and sharing additional data when available. Disclosure: I am an employee at Biogen.  Citation: T rial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus Richard A. Furie, M.D., Ronald F. van Vollenhoven, M.D., Kenneth Kalunian, M.D., Sandra Navarra, M.D., Juanita Romero-Diaz, M.D., Victoria P. Werth, M.D., Xiaobi Huang, Ph.D., George Clark, B.S., Hua Carroll, M.D., Adam Meyers, M.S., Cristina Musselli, M.D., Catherine Barbey, Ph.D., et al., for the LILAC Trial Investigators* September 8, 2022 N Engl J Med 2022; 387:894-904 DOI: 10.1056/NEJMoa2118025 https://www.nejm.org/doi/full/10.1056/NEJMoa2118025 The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.     Read the full article
0 notes
mundoagrocba · 2 years
Text
La raza Bosmara prepara su Primer Gran Remate en la Sociedad Rural de Jesús María
La raza Bosmara prepara su Primer Gran Remate en la Sociedad Rural de Jesús María
Será el próximo jueves 4 de agosto, de la mano de cabañas del Norte de Córdoba. Un grupo de tres cabañas del Norte de Córdoba, dedicadas a la actividad ganadera y con un fuerte foco en la raza Bosmara, organizan un Remate de hacienda con animales con la genética mencionada. Animales que tienen, como principal característica, la adaptación a climas inhóspitos, muy buenos para cruzamientos con…
Tumblr media
View On WordPress
0 notes
don-lichterman · 2 years
Text
Biogen Explores Music Therapy To Improve Walking In MS Through Partnership With MedRythms
Biogen Explores Music Therapy To Improve Walking In MS Through Partnership With MedRythms
Young caucasian woman listening music at home. getty Today marks the fourteenth annual World MS Day – a day to reflect on the experiences, challenges and aspirations of the 2.5 million people around the world living with multiple sclerosis. A neurological condition principally diagnosed in adults between the ages of 20 and 40 – some of the disease’s defining features and hardest to treat…
Tumblr media
View On WordPress
0 notes
deinheilpraktiker · 1 year
Text
Das Amyloid-PET-Scannen hat die FDA dazu verleitet, die Zulassung für Aduhelm zu erteilen Im vergangenen Jahr erteilte die FDA eine beschleunigte Zulassung des Antikörpers Aducanumab (vermarktet als Aduhelm von Biogen) zur Behandlung der Alzheimer-Krankheit. Die Zulassung basierte ausschließlich auf einer mutmaßlichen Verringerung der Menge des Proteins „Amyloid“ im Gehirn, wie durch Amyloid-PET-Scans festgestellt, und ohne Nachweis einer signifikanten klinischen Wirkung. In einem im Journal of Alzheimer's Disease veröffentlichten Kommentar haben die Autoren Poul F... #Alzheimer_Erkrankung #Antikörper #Bildgebung #Biogen #Drogen #Forschung #Gehirn #Gesundheitswesen #Immuntherapie #Krankenhaus #Protein #Radiologie
0 notes